Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking

SARS-CoV-2 therapeutic antibody discovery efforts have met with notable success but have been associated with a generally inefficient process, requiring the production and characterization of exceptionally large numbers of candidates for the identification of a small set of leads. Here, we show that...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:bioRxiv
Κύριοι συγγραφείς: Shiakolas, Andrea R., Johnson, Nicole, Kramer, Kevin J., Suryadevara, Naveenchandra, Wrapp, Daniel, Periasamy, Sivakumar, Pilewski, Kelsey A., Raju, Nagarajan, Nargi, Rachel, Sutton, Rachel E., Walker, Lauren, Setliff, Ian, Crowe, James E., Bukreyev, Alexander, Carnahan, Robert H., McLellan, Jason S., Georgiev, Ivelin S.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Cold Spring Harbor Laboratory 2021
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183015/
https://ncbi.nlm.nih.gov/pubmed/34100018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.06.02.446813
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια